Kathleen I Pritchard

Kathleen I Pritchard

UNVERIFIED PROFILE

Are you Kathleen I Pritchard?   Register this Author

Register author
Kathleen I Pritchard

Kathleen I Pritchard

Publications by authors named "Kathleen I Pritchard"

Are you Kathleen I Pritchard?   Register this Author

100Publications

4591Reads

38Profile Views

Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?

Clin Breast Cancer 2020 Feb 11;20(1):e54-e64. Epub 2019 Jul 11.

Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.06.007DOI Listing
February 2020

The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.

NPJ Breast Cancer 2020 21;6. Epub 2020 Feb 21.

10Division of Medical Oncology & Hematology, Sunnybrook Odette Cancer Center, Ontario Clinical Oncology Group, University of Toronto, Toronto, ON Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-020-0149-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035359PMC
February 2020

Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective.

Breast 2019 Nov;48 Suppl 1:S21-S22

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0960-9776(19)31116-6DOI Listing
November 2019

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

N Engl J Med 2019 06 3;380(25):2395-2405. Epub 2019 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709671PMC
June 2019

Bone-Targeted Therapy in Early Breast Cancer.

Oncology (Williston Park) 2018 11;32(11):562-9

View Article

Download full-text PDF

Source
November 2018

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2018 Jul 3;379(2):111-121. Epub 2018 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804710
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172658PMC
July 2018

An update on treatment for post-menopausal metastatic breast cancer in elderly patients.

Expert Opin Pharmacother 2018 04;19(6):597-609

a Department of Medicine , Sunnybrook Odette Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1454431DOI Listing
April 2018

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.

Eur J Cancer 2018 03 11;91:38-46. Epub 2018 Jan 11.

Institute of Health Policy, Management and Evaluation, University of Toronto, Canada; Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.010DOI Listing
March 2018

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

J Clin Oncol 2018 02 12;36(6):563-571. Epub 2018 Jan 12.

Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto; Timothy J. Whelan, McMaster University and Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada; Paul E. Goss, Massachusetts General Hospital Cancer Center, Boston, MA; James N. Ingle, North Central Cancer Treatment Group, Mayo Clinic, Rochester, NY; Paul Celano; Greater Baltimore Medical Center, Baltimore, MD; Hyman Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Julie Gralow, University of Washington, Seattle, WA; and Kathrin Strasser-Weippl, Wilhelminen Hospital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.7500
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.7500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815404PMC
February 2018

Extended adjuvant therapy: the role of subset analyses.

Lancet Oncol 2017 11 12;18(11):1431-1433. Epub 2017 Oct 12.

Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30787-8DOI Listing
November 2017

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

N Engl J Med 2017 11;377(19):1836-1846

From the Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford (H.P., R.G., J. Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734609PMC
November 2017

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

J Clin Oncol 2017 May 20;35(15):1641-1649. Epub 2017 Mar 20.

Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.0722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548226PMC
May 2017

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

J Clin Oncol 2017 Apr 23;35(10):1041-1048. Epub 2017 Jan 23.

Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2871DOI Listing
April 2017

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Oncologist 2017 01 18;22(1):12-24. Epub 2016 Nov 18.

Division of Medical Oncology, Dalhousie University, and Atlantic Clinical Cancer Research Unit, Halifax, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313264PMC
January 2017

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Eur J Cancer 2017 01 2;70:143-145. Epub 2016 Dec 2.

Sunnybrook Research Institute, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.11.002DOI Listing
January 2017

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?

Eur J Cancer 2016 11 19;68:173-175. Epub 2016 Oct 19.

Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.08.021DOI Listing
November 2016

Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence.

Eur J Cancer 2016 11 21;68:176-178. Epub 2016 Oct 21.

Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.09.007DOI Listing
November 2016

An update on adjuvant systemic therapy for elderly patients with early breast cancer.

Expert Opin Pharmacother 2016 Oct 19;17(14):1881-8. Epub 2016 Aug 19.

a Department of Medicine , University of Toronto , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1219339DOI Listing
October 2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

J Natl Cancer Inst 2016 08 20;108(8). Epub 2016 Apr 20.

Department of Medicine, Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium (AS, EdA, MP, HAAJr); Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, UK (DAt, IB, CC); Novartis Pharmaceuticals Corporation, East Hanover, NJ (YH); Alliance Statistics and Data Center, Mayo Clinic, Section of Biostatistics, Scottsdale, AZ (ACD); Sunnybrook Odette Cancer Centre, the University of Toronto and the NCIC Clinical Trials Group, Toronto, Ontario, Canada (KIP); The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (ACW); Sana Klinikum Offenbach, Offenbach, Germany (CJ); National Institute of Oncology, Budapest, Hungary (IL); Helios Klinikum Berlin-Buch, Berlin, Germany (MU); Royal Marsden Hospital NHS Trust, Sutton/Surrey, UK (IS); Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, Australia (FB); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (BX); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (HG); Mayo Clinic, Jacksonville, FL (EAP)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017935PMC
August 2016

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.

Breast Cancer Res Treat 2016 08 18;158(3):407-20. Epub 2016 Jul 18.

Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3906-9DOI Listing
August 2016

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

N Engl J Med 2016 Jul 5;375(3):209-19. Epub 2016 Jun 5.

From the Massachusetts General Hospital Cancer Center, Avon International Breast Cancer Research Program (P.E.G.), Harvard Medical School (P.E.G., E.W.), and Dana-Farber Cancer Institute (E.W.), Boston; the Department of Oncology, Mayo Clinic, Rochester, MN (J.N.I., J.S.K.); Sunnybrook Odette Cancer Centre, Toronto (K.I.P.), British Columbia Cancer Agency, Vancouver (K.G.), Canadian Cancer Trials Group, Queen's University, Kingston, ON (K.W., D.T., W.R.P.), Department of Oncology, McMaster University, Hamilton, ON (T.W.), and Dalhousie University Faculty of Medicine, Moncton Hospital, Moncton, NB (S.R.) - all in Canada; Virginia Cancer Specialists-US Oncology Network, Fairfax (N.J.R.); University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill (H.M.); University of Washington School of Medicine, Seattle (J.G.); Center of Oncology and Hematology, Wilheminen Hospital, Vienna (K.S.-W.); Colorado Cancer Research Program, Denver (K.S.); Johns Hopkins Kimmel Cancer Center, Baltimore (A.C.W.); Memorial Sloan Kettering Cancer Center, New York (C.H.); University of Arizona, Tucson (A.S.); and Highlands Oncology Group, Fayetteville, AR (J.T.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1604700DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024713PMC
July 2016

Update of the oxford overview: new insight and perspectives in the era of personalized medicine.

Am Soc Clin Oncol Educ Book 2012 :71-9

From the Odette Cancer Center, McMaster University, Hamilton, ON, Karolinska Institutet, Stockholm, Sweden, and the Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.199DOI Listing
April 2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

J Clin Oncol 2016 Apr 23;34(10):1065-71. Epub 2015 Nov 23.

Mark N. Levine, Jim A. Julian, and Louise Bordeleau, McMaster University, Hamilton; Mark N. Levine and Louise Bordeleau, Hamilton Health Sciences Juravinski Cancer Centre, Hamilton; Mark N. Levine and Jim A. Julian, Ontario Clinical Oncology Group and Escarpment Cancer Research Institute, Hamilton; Philippe L. Bedard, Andrea Eisen, Maureen E. Trudeau, and Kathleen I. Pritchard, University of Toronto, Toronto; Phillipe L. Bedard, Princess Margaret Hospital, Toronto; Andrea Eisen, Maureen E. Trudeau, and Kathleen I. Pritchard, Odette Sunnybrook Regional Cancer Centre; Toronto; and Brian Higgins, Peel Regional Cancer Centre, Mississauga, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.8503DOI Listing
April 2016

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer.

Support Care Cancer 2016 Mar 11;24(3):1097-105. Epub 2015 Aug 11.

Division of Medical Oncology, Sunnybrook Odette Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-015-2883-6
Publisher Site
http://dx.doi.org/10.1007/s00520-015-2883-6DOI Listing
March 2016

Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.

J Clin Oncol 2016 Mar 19;34(9):895-7. Epub 2016 Jan 19.

University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.2255DOI Listing
March 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2015 Nov 27;373(21):2005-14. Epub 2015 Sep 27.

From the Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.) and Juravinski Cancer Center, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), Duke University Medical Center, Durham (J.A.O.), Wake Forest University Health Service, Winston-Salem (L.I.W.), and Southeast Clinical Oncology Research Consortium, Goldsboro (J.N.A.) - all in North Carolina; Mayo Clinic, Jacksonville, FL (E.A.P.); University of Maryland School of Medicine, Baltimore (J.A.O.), and National Institutes of Health, Bethesda (J.Z., T.L.) - both in Maryland; Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.) - both in Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Baylor College of Medicine, Houston (M.J.E.), and University of Texas, San Antonio (P.R.) - both in Texas; Washington University, St. Louis (M.J.E.); Allegheny General Hospital (S.P.) and University of Pittsburgh (A.M.B.) - both in Pittsburgh; the Department of Medical Oncology and Breast Center, Yonsei University College of Medicine, Seoul, South Korea (S.P.); Emory University, Atlanta (W.C.W.); Irish Clinical Oncology Research Group, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); University of Hawaii Cancer Center, Honolulu (J.L.B.); and Stanford University, Stanford, CA (G.W.S.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701034PMC
November 2015

Regional Nodal Irradiation in Early-Stage Breast Cancer.

N Engl J Med 2015 Jul;373(4):307-16

From the Department of Oncology, McMaster University, and Juravinski Cancer Centre, Hamilton, ON (T.J.W., M.N.L.), Tom Baker Cancer Centre, Calgary, AB (I.A.O., P.C.), BC Cancer Agency-Vancouver Island Centre, Victoria, BC (I.A.O.), Queen's University and NCIC Clinical Trials Group, Kingston, ON (W.R.P., Y.M., J.-A.W.C., B.E.C.), University of Toronto and Sunnybrook Odette Cancer Centre, Toronto (I.A., K.I.P.), Centre Universitaire de Sherbrooke at Fleurimont Hospital, Sherbrooke, QC (A.N.), Université de Montréal, Montreal (P.R.), Laval University and L'Hôtel-Dieu de Québec, Quebec, QC (A.F.), Princess Margaret Hospital, Toronto (L.M., D.R.M.), Cross Cancer Institute, Edmonton, AB (S.C.), Nova Scotia Cancer Centre, Halifax (M.C.N), Northeastern Ontario Regional Cancer Centre, Sudbury (J.B.), and BC Cancer Agency-Vancouver Centre, Vancouver, BC (K.G.) - all in Canada; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.H.C.); Cancer Research UK-Medical Research Council Oxford Institute for Radiation Oncology, Oxford, United Kingdom (K.A.V.); Ohio State University Wexner Medical Center, Columbus (J.R.W.); and the University of Michigan Comprehensive Cancer Center, Ann Arbor (L.J.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1415340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556358PMC
July 2015

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.

Breast Cancer Res Treat 2015 Jun 12;151(3):639-52. Epub 2015 May 12.

Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Suite 658, 144 College Street, Toronto, ON, M5S 3M2, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3382-7DOI Listing
June 2015

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

J Clin Oncol 2015 May 16;33(14):1574-83. Epub 2015 Mar 16.

Karen A. Gelmon, David G. Huntsman, and Samuel Aparicio, British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver; Susan L. Ellard, British Columbia Cancer Agency, Cancer Centre for the Southern Interior, Kelowna, British Columbia; Julie Lemieux, Centre Hospitalier Affilié Hopital Du St Sacrement, Quebec City, Quebec; Lois E. Shepherd, Dora Nomikos, Judith-Anne W. Chapman, and Wendy R. Parulekar, NCIC Clinical Trials Group, Queen's University, Kingston; Susan Dent, Ottawa Health Research Institute, Ottawa; Kathleen I. Pritchard, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto; Timothy J. Whelan, Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario; Katia Tonkin, Cross Cancer Institute, Edmonton, Alberta, Canada; Frances M. Boyle, Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, North Sydney, New South Wales, Australia; Bella Kaufman, Sheba Medical Centre, Tel Hashomer; Shulamith Rizel, Rabin Medical Center, Petach Tikva, Israel; Alexey Manikhas, City Clinical Oncological Dispensery, St Petersburg; Sergei Tjulandin, Russian Cancer Research Center, Moscow; Rustem Khasanov, Clinical Oncology Dispensary, Kazan, Russia; Angelo Di Leo, Sandro Pitgliani Medical Oncology Unit, Prato, Italy; Miguel Martin, Servicio Oncologia Hospital Gregorio Marañon, Madrid, Spain; Lee S. Schwartzberg, West Clinic, Memphis, TN; Arnd Nusch, Praxis, Velbert, Germany; Robert E. Coleman, Weston Park Hospital, Cancer Research Centre, Sheffield, United Kingdom; Hirofumi Mukai, National Cancer Center Hospital East, Kashiwa-shi, Japan; Anne P. Connor, GlaxoSmithKline, Collegeville, PA; and Sergio L. Santillana, GlaxoSmithKline, Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/14/1574.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.9590
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.9590DOI Listing
May 2015

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

J Clin Oncol 2015 May 20;33(15):1680-7. Epub 2015 Apr 20.

John M.S. Bartlett, Ontario Institute for Cancer Research; Frances P. O'Malley, St Michael's Hospital; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto; John M.S. Bartlett, Frances P. O'Malley, and Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group; Lois E. Shepherd, Queen's University, Kingston, Canada; John M.S. Bartlett, Alison F. Munro, and David A. Cameron, University of Edinburgh, Edinburgh; Christopher C. McConkey, Janet A. Dunn, and Christopher J. Poole, University of Warwick, Coventry; Helena M. Earl and Carlos Caldas, University of Cambridge, Cambridge; Christopher J. Twelves, St James's University Hospital, Leeds; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Christine Desmedt and Denis P. Larsimont, Université Libre de Bruxelles, Brussels, Belgium; Fatima Cardoso, Champalimaud Cancer Centre, Lisbon, Portugal; Maj-Britt Jensen and Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; and Angelo Di Leo, Hospital of Prato, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.7869DOI Listing
May 2015

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425383PMC
May 2015

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

J Natl Cancer Inst 2015 Mar 4;107(3). Epub 2015 Mar 4.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565534PMC
March 2015

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

J Clin Oncol 2015 Jan 15;33(3):265-71. Epub 2014 Dec 15.

Vered Stearns, Kimmel Cancer Center, Johns Hopkins, Baltimore, MD; Judith-Anne W. Chapman, Aurélie Le Maitre, Jessica Kundapur, and Lois E. Shepherd, NCIC Clinical Trials Group, Queen's University, Kingston; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Cynthia X. Ma, Siteman Cancer Center, Washington University, St Louis, MO; Matthew J. Ellis, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; James N. Ingle, Mayo Clinic, Rochester, MN; G. Thomas Budd, Cleveland Clinic, Cleveland, OH; George W. Sledge, Stanford University, San Francisco, CA; Pedro E.R. Liedke and Paul E. Goss, Harvard University; Paul E. Goss, Avon International Breast Cancer Research Program, Massachusetts General Hospital, Boston, MA; Manuela Rabaglio, Inselspital University Hospital and International Breast Cancer Study Group Coordinating Center, Berne, Switzerland; and Pedro E.R. Liedke, Hospital de Clínicas de Porto Alegre and Instituto do Cancer Mãe de Deus, Oncologia, Porto Alegre, Rio Grande do Sul, Brazil.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/265.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6926
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289722PMC
January 2015

Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.

Breast Cancer Res Treat 2015 Jan 27;149(1):293-301. Epub 2014 Dec 27.

Department of Medicine, University of Toronto, 27 King's College Cir, Toronto, ON, M5S 1A1, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-014-3235-9
Publisher Site
http://dx.doi.org/10.1007/s10549-014-3235-9DOI Listing
January 2015

The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care?

Oncology (Williston Park) 2015 Jan;29(1):23-30, 37

View Article

Download full-text PDF

Source
January 2015

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.

Breast Cancer Res Treat 2014 Jul 13;146(1):153-62. Epub 2014 Jun 13.

Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute and University of Ottawa, Box 912, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3015-6DOI Listing
July 2014

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

J Clin Oncol 2014 Jul 16;32(21):2231-9. Epub 2014 Jun 16.

Pamela J. Goodwin, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and Princess Margaret Hospital; Kathleen I. Pritchard, Sunnybrook Odette Cancer Center; Pamela J. Goodwin and Kathleen I. Pritchard, University of Toronto, Toronto; Roanne J. Segal, Ottawa Hospital Regional Cancer Center, University of Ottawa, Ottawa; Gregory R. Pond, Som Mukherjee, and Mark Levine, Juravinski Hospital and Cancer Center; Brian Findlay, Niagara Health System, Walker Family Cancer Center; Gregory R. Pond, Mark Levine, Brian Findlay, and Som Mukherjee, McMaster University, Hamilton, Ontario; Michael Vallis, Dalhousie University, Halifax, Nova Scotia; André Robidoux, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Jennifer A. Ligibel, Dana-Farber Cancer Institute; George L. Blackburn, Beth Israel Deaconess Medical Center; Jennifer A. Ligibel and George L. Blackburn, Harvard Medical School, Boston, MA; and Julie R. Gralow, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.1517DOI Listing
July 2014

The impact of a breast cancer diagnosis in young women on their relationship with their mothers.

Breast 2014 Feb 27;23(1):50-5. Epub 2013 Nov 27.

Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.10.004DOI Listing
February 2014

Overdiagnosing overdiagnosis.

Oncologist 2014 Feb;19(2):103-6

Sunnybrook Research Institute and Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Department of Medical Biophysics and Medical Imaging, University of Toronto, Toronto, Ontario, Canada; Smarter Imaging Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926799PMC
February 2014

Validated or not validated? That is the question.

J Natl Cancer Inst 2014 Jan;106(1):djt360

Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djt360DOI Listing
January 2014

Symptoms and cancer outcome in adjuvant endocrine therapy for breast cancer: why are they associated?

J Clin Oncol 2013 Dec 4;31(35):4476. Epub 2013 Nov 4.

Sunnybrook Research Institute, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.4280DOI Listing
December 2013

Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer.

J Clin Oncol 2013 Oct 16;31(30):3758-63. Epub 2013 Sep 16.

Ian S. Dayes, Tim J. Whelan, Jim A. Julian, Sameer Parpia, and Mark N. Levine, McMaster University; Tim J. Whelan, Jim A. Julian, Sameer Parpia, Kathleen I. Pritchard, and Mark N. Levine, Ontario Clinical Oncology Group; Ian S. Dayes, Tim J. Whelan, and Mark N. Levine, Juravinski Cancer Centre; Donna Reise, Talspar Nursing Services; Jennifer Wiernikowski, Hamilton Health Sciences, Hamilton; Kathleen I. Pritchard and Lee Manchul, University of Toronto; Kathleen I. Pritchard, Odette Sunnybrook Cancer Centre; Lee Manchul, University Health Network, Toronto; David Paul D'Souza and Lyn Kligman, London Regional Cancer Program, London; David Paul D'Souza, University of Western Ontario, London, Ontario; Linda LeBlanc, Dr Leon Richard Oncology Centre, Moncton, New Brunswick; Margaret L. McNeely, University of Alberta; and Margaret L. McNeely, Cross Cancer Institute, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.7192DOI Listing
October 2013

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.

Cancer Treat Rev 2012 Oct 23;38(6):673-88. Epub 2012 Feb 23.

Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.12.002DOI Listing
October 2012

Personalized medicine: what exactly is it and can we truly measure it?

J Clin Oncol 2012 Jun 14;30(18):2173-4. Epub 2012 May 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.41.8889DOI Listing
June 2012

Adjuvant endocrine therapy for breast cancer: a commentary.

Oncology (Williston Park) 2012 Jun;26(6):568, 570

Sunnybrook Odette Cancer Centre, Toronto, Ontario.

View Article

Download full-text PDF

Source
June 2012

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

Eur J Cancer 2012 Mar 22;48(4):475-81. Epub 2011 Dec 22.

Department of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.11.021DOI Listing
March 2012

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

J Natl Cancer Inst 2012 Mar 6;104(6):427-8. Epub 2012 Mar 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs139DOI Listing
March 2012

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.

Breast Cancer Res Treat 2012 Jan 1;131(2):541-51. Epub 2011 Nov 1.

Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1840-4DOI Listing
January 2012

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

J Clin Oncol 2012 Jan 12;30(2):164-71. Epub 2011 Dec 12.

Mount Sinai Hospital, 1284-600 University Ave, Toronto, Ontario M5G 1X5, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.36.2723
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.36.2723DOI Listing
January 2012

Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14.

J Clin Oncol 2011 Sep 22;29(27):3605-10. Epub 2011 Aug 22.

Penn State Hershey Cancer Institute, Division of Hematology/Oncology, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.31.5069
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.31.5069DOI Listing
September 2011